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A B S T R A C T Patients from two families with chronic
hemolytic anemia have been studied. The erythrocytes
are very fragile and appear microcytic with a great
variety of shapes. Clinical evaluation failed to identify
traditionally recognized causes of hemolysis. Sodium
dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) showed no significant abnormality of the
major polypeptide bands. Erythrocytes spectrin-ankyrin
and ankyrin-membrane interactions were analyzed
with 125I-labeled spectrin, 125I-labeled ankyrin, and
inside-out vesicles. Patients' vesicles bound 125I-spectrin
normally. Likewise, patients' spectrin and ankyrin
competed normally for the binding sites on control
membranes. None of the individual components ap-
peared to have abnormal thermal sensitivity. Ankyrin-
stripped, inside-out vesicles prepared from the patients
bound less 125I-ankyrin than did vesicles prepared from
normals (P < 0.05 for all corresponding points in the
high-affinity region). Scatchard analysis showed the most
significant abnormality to be a 50% reduction in the
high affinity ankyrin binding sites. Similar experiments
were performed with blood from patients with
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spherocytosis and splenectomized controls, but no ab-
normalities were detected. The water soluble 43,000-
dalton fragments of band 3 (the high-affinity ankyrin
binding sites) were prepared from one of the patients
and competed normally for 125I-ankyrin binding in
solution. This suggests that the primary structural
defect is a reduction in the number of high affinity
membrane binding sites for ankyrin, and is consistent
with an abnormal organization of band 3 in the
membrane.
INTRODUCTION
The molecular structure of the erythrocyte membrane
has been extensively studied (1-3). It contains a
membrane-associated cytoskeleton responsible for the
unusual stability ofthis cell in circulation, and it retains
the shape of the original cell after extraction with
nonionic detergents (1, 4). The cytoskeleton is
composed of spectrin, band 4.11 and erythrocyte actin,
as well as some other associated polypeptides. Ghosts
rapidly disintegrate into small vesicles after selective
extraction of spectrin and actin (1). Spectrin has been
shown to exist on the membrane as a tetramer consist-
ing of two dimers associated head to head (5, 6), and
ghosts with spectrin principally in the dimer form are
unstable (7). Spectrin has also been shown to bind to
erythrocyte actin and band 4.1 (8-10). Spectrin dimers
have been visualized by low angle rotary shadowed
1 Nomenclature of Steck (1).
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FIGURE 1 Scanning electron micrographs of erythrocytes from a normal individual (A) and
hemolytic patient A.P. (B).
electron microscopy with identification ofbinding sites
for ankyrin, band 4.1, and actin as well as the site of
tetramer formation (6, 11). Functional domains of
spectrin have been identified by peptide fragment
analysis (12).
Abnormalities of spectrin are sometimes associated
with gross abnormalities in erythrocyte shape. Mutant
strains of mice have been reported that are deficient
in spectrin and have extremely fragile spherocytic
erythrocytes (13, 14). Pyropoikilocytosis is a disorder
of erythrocytes characterized by abnormal temperature-
sensitive cell fragmentation (15), and the spectrin has
been shown to have increased sensitivity to thermal
denaturation (16). Some kindreds with elliptocytosis
also appear to have spectrin with slightly increased
heat sensitivity (17), and spectrin from a similar patient
was shown to yield abnormal trypsin digestion frag-
ments (18). Other reports indicate that other forms
of elliptocytosis may be due to alterations in spectrin
tetramer-dimer equilibrium (19) or reductions in the
amount of band 4.1 (20, 21).
Direct association of cytoskeletal proteins with
membrane components has been demonstrated (22-24).
Spectrin binds with high affinity to band 2.1, a poly-
peptide localized on the inner surface ofthe membrane
named "ankyrin" (25-28) which has been purified (11,
29). Ankyrin binds directly to the membrane at a site
identified as the cytoplasmic domain of band 3 (30).
We searched for defects in this linkage in abnormally
shaped erythrocytes. Two families were located with
hemolytic poikilocytic anemia, and reductions in the




Individuals from two unrelated families were studied in
detail. Affected members had varying degrees of icterus and
anemia and their erythrocytes have bizarre morphology
(Fig. 1). Clinical evaluation ruled out abnormalities of
hemoglobin, glycolytic enzymes, autoimmunity, and nutrition
because the following determinations were normal: serum
iron, transferrin, ferritin, vitamin B,2 and folate, free erythro-
cyte protoporphyrin, hemoglobin electrophoresis, a:,8-globin
ratios, glycolytic enzymes, direct and indirect Coombs, and
fibrin degradation products. Preliminary heat-induced frag-
mentation studies showed no significant temperature shift.
Studies with 51Cr-labeled erythrocytes from patient D.W.
before splenectomy showed a survival of 15 d (normal 26-
35 d). Cells from patients had slightly increased hypotonic
lysis before splenectomy (midpoint 0.48% NaCl, normal
0.39-0.46%) and greatly increased hypotonic lysis after
splenectomy (midpoint 0.57% NaCl). Increased autohemoly-
sis was noted (7.8 and 10.8%, normal <3%) and was
partially corrected with glucose (1.9 and 2.7%, normal <1%).
All three patients underwent splenectomy, which resulted in
an improvement of the anemia (Table I), although the
abnormal erythrocyte morphology persisted.
North Carolina family. The index case, A.P., is a 23-yr-
old black male with chronic anemia who first required a blood
transfusion at age 5 yr. Scleral icterus was noted intermittently,
and he was referred to the University of North Carolina at
age 18. He had splenomegaly but looked well. He underwent
splenectomy and now enjoys excellent health. A younger
sister (H.P.) has similar erythrocytes and recently underwent
splenectomy with cholecystectomy resulting in clinical
improvement. An older brother (H.W.P.) has similar erythro-
cytes but compensated hemolysis. The other three siblings
and both parents are healthy and have normal erythrocytes.
Mistaken paternity has been excluded with a survey ofgenetic
markers. Also, inheritance of Rh antigens was not clearly
linked with the erythrocyte defect, and sulfate flux studies
were normal.
Ontario family. The index case, D.W., is a 65-yr-old
Caucasian woman with chronic hemolytic poikilocytic anemia
that was exacerbated by gastrointestinal bleeding 14 yr ago.
After splenectomy she improved clinically and enjoys good
health. Her son (P.W.) was found to have uniformly ellipto-
cytic erythrocytes, but is not significantly anemic. None ofher
other relatives have histories of blood disorders, and all of
those checked have normal peripheral blood smears.
Control blood samples were also obtained from many un-
related individuals including several healthy adults with
normal erythrocytes, five adults with varying degrees of
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TABLE I
Summary of Clinical Data
Hemoglobin Reticulocytes
Pre- Post- Pre- Post-
Family and race Patient splenectomy splenectomy* splenectomy splenectomy* MCVt Erythrocyte morphology
gIlOO ml %
North Carolina A.P.§ 10.4 13.4 13.6 2.2 56 Marked poikilocytosis,
Black anisocytosis, and
microcytosis
H.P. (sister) 9.0 13.3 7.6 1.9 58 Similar to A.P.
H.W.P."1 (brother) 13.3 7.2 73 Similar to A.P.
Mother 12.5 1.6 81 Normal
Father 12.5 1.3 84 Normal
Ontario D.W.§ 7.5 10.5 11.4 2.3 63 Marked poikilocytosis,Caucasian anisocytosis, and
microcytosis
P.W. (son) 13.1 2.3 85 Elliptocytosis
B.W. (son) 14.0 86 Normal
J. B. (daughter) 13.1 88 Normal
* Blood drawn at least 6 wk after splenectomy.
t Mean corpuscular volume, fluid.
§ Index case of family.
"H.W.P. subsequently developed hepatitis and was not included in the ankyrin binding studies.
spherocytosis, and three adults who had undergone sple-
nectomies because of other problems.
Materials
'25I-Bolton-Hunter Reagent (2,000 Ci/mmol) was from New
England Nuclear, Boston, Mass. a-Chymotrypsin (70 U/mg)
FIGURE 2 Membrane preparations from the North Carolina
family were analyzed by SDS-PAGE on 7% 3-mm thick slab
gels and stained with Coomassie Blue. Approximately 50 Ag
protein of erythrocyte ghosts were applied (lanes A-E),
-25 Ag protein of inside-out vesicles (lanes F, H-J, but note
-35 ,ug protein in lane G), 15 Ag protein of ankyrin-stripped
inside-out vesicles (lanes K-O), and 3 pLg protein of partially
purified ankyrin (lanes Q and R). The corresponding prepara-
tions from patient A.P. are in lanes B, C, L, and R, patient
H.P. in lanes C, H, and M, their mother (normal RBC) in
lanes A, F, and K, their father (normal RBC) in lanes D, I, and
N, and an unrelated normal individual in lanes E, J, 0, and Q.
was from Worthington Biochemicals, Freehold, N. J.
Acrylamide, ammonium persulfate, sodium dodecyl sulfate
(SDS), and Coomassie Brillant Blue were from Bio-Rad
Laboratories, Richmond, Calif. DEAE-cellulose (DE 52) was
from Whatman Inc., Clifton, N. J.
Preparative methods
Venous blood samples were anticoagulated with acid
citrate-dextrose and stored at 0° C for up to 24 h. Washed
erythrocytes were hypotonically lysed as described (27). The
viscous leukocyte pellet was carefully removed by aspiration,
and the ghosts were washed repeatedly until those from
normal cells were white. Ghosts from patients with each ofthe
various hemolytic anemias usually remained slightly pink
unless washed more extensively. Inside-out vesicles depleted
of spectrin and actin and ankyrin-stripped, inside-out
vesicles were prepared taking precautions to avoid proteolysis
as described (25, 26, 31, 32).
Spectrin heterodimer was purified to homogeneity from
erythrocytes of normal individuals as described (31, 33). Pure
spectrin was radiolabeled with '25I-Bolton-Hunter reagent
essentially as described for radiolabeling ankyrin (32). After
dilution with pure unlabeled spectrin, the specific activities
of the different preparations ranged between 70,000 and
285,000 cpm/,ug. Ankyrin was purified to homogeneity from
the erythrocytes of normal individuals as described (29) and
was radiolabeled with 125I-Bolton-Hunter reagent (32). After
dilution with unlabeled ankyrin, the final specific activities
ranged between 50,000 and 90,000 cpm/,ug. Note that in all
experiments 1251-spectrin and 125I-ankyrin refer to radio-
labeled pure protein prepared from normal individuals.
Ankyrin for competition experiments was partially purified by
selective extraction of the cytoskeletons.
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Assay methods
Binding of 2-5I-spectrin to inside-out vesicles was measured
as reported (31). Samples of l25I-spectrin were heat-denatured
(70° C, 10 min) and were tested at every 125I-spectrin con-
centration for each patient in each experiment to estimate
nonspecific binding. Such measurements showed -10% ofthe
total counts per minute bound to be nonspecific, and the
measured value was routinely subtracted. All spectrin binding
experiments are presented with each point representing
duplicates and had ranges of <±6%.
Binding of 125I-ankyrin to ankyrin-stripped, inside-out
vesicles was measured as reported (32). 125I-Ankyrin (1-50 ,ug,
50,000 to 90,000 cpm/4Lg) and ankyrin-stripped, inside-out
vesicles (6-13 ,ug membrane protein) were incubated in 0.2 ml
vol for 150 min at 240C. Free and membrane-bound [125]_
ankyrin were separated and nonspecific binding (which was
generally - 10% of the total) was measured for each point and
corrected as described above. All values represent duplicates
or triplicates and had ranges of < +6%. The l25I-ankyrin bind-
ing data were fitted to the four parameter Scatchard model
(34, 35) with Scatchard model test data, a nonlinear computer
analysis (36).
Scanning electron microscope studies were performed on
aliquots of the blood samples that were diluted into pre-
filtered 0.1 M sodium phosphate, 3% glutaraldehyde, pH 7.4
immediately after blood-drawing. Membrane protein was
estimated (37) using bovine serum albumin as the standard.
Spectrin, ankyrin, and 43,000-dalton fragments ofband 3 were
estimated by absorbance at 280 nM. SDS-polyacrylamide
gel electrophoresis (PAGE) was performed essentially by the
method of Fairbanks (38).
RESULTS
SDS-PAGE was performed on membranes and vesicles
at each stage of preparation, and there is no significant
abnormality of the major polypeptide bands (Fig. 2).
In the ghosts (lanes A-E) band 8 and hemoglobin
appear increased in patient preparations but can be
reduced by more extensive washing. This is also seen
in ghosts from several other sorts of hemolytic anemias
and probably represents adherent protein rather than
protein trapped in right-side-out vesicles. Spectrin-
stripped, inside-out vesicles (lanes F-J) appear
equivalent. Ankyrin-stripped, inside-out vesicles (lanes
K-O) consisted of identical amounts of band 3 and
periodic acid-Schiff (PAS) staining (not shown), which
are the principal polypeptides remaining. Special care
was taken to detect residual ankyrin on the vesicles,
but the tiny amount (<5%) of spectrin and ankyrin
remaining did not correlate with reductions of [125I]_
ankyrin binding. Spectrin (not shown) and ankyrin
were partially purified from each of the patients and
controls, and no differences in quantity or electro-
phoretic mobility were noted. Proteolysis was a con-
cern so precautions were taken to avoid it, and in-
spection of the gels failed to demonstrate evidence of
any proteolysis. SDS-PAGE of preparations from
members of the Ontario family were also essentially
normal (not shown).
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FIGURE 3 Effect of increasing the concentration of '25I-spec-
trin on binding to inside-out vesicles. The '25I-spectrin, in
this and all experiments, was prepared from a normal individ-
ual. The inside-out vesicles were prepared from patients
(A, A.P., N. C., above; and O, D.W., Ontario, below) and nor-
mals (0). Various concentrations of '251-spectrin were in-
cubated at 0° C in a 0.2-ml vol with the corresponding inside-
out vesicles (9 ,ug membrane protein). Specifically membrane
bound and free radioactivity were determined for each point.
These data are plotted according to the Scatchard equation
in the insets.
sites for spectrin on the membrane (ankyrin) were
examined by comparing the capacities of patient and
control inside-out vesicles to bind 125I-spectrin hetero-
dimer prepared from normal erythrocytes (Fig. 3).
Increasing concentrations of 125I-spectrin were in-
cubated with constant amounts of inside-out vesicles,
and the total binding capacities and affinities were
identical. Although higher capacities were measured in
other experiments, the values obtained from patients
and controls were always identical within each experi-
ment, which indicates that there is no significant differ-
ence in the spectrin binding sites.
Binding ofspectrin and ankyrin is normal. Various
concentrations of unlabeled spectrin (from patients or
controls) were incubated with a constant amount of
125I-spectrin and a constant amount ofcontrol inside-out
vesicles. Unlabeled spectrin competed with 1251-
spectrin for the binding sites, and spectrin samples
from patients and controls appeared equivalent (Table
II). Similar experiments were also performed with
unlabeled ankyrin, and patient and control prepara-
tions again appeared equivalent (Table II). Spectrin
from patients with hereditary pyropoikilocytosis (16)
is more sensitive to heat denaturation than normal
spectrin. Spectrin from patient A.P. and a control were
preincubated at several temperatures above 50° C with
identical loss ofbinding ability. Likewise, ankyrin from
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TABLE II
Competitive Inhibition of 125I-Spectrin
and 1251-Ankyrin Binding*
Unlabeled Inhibition
protein jLg/ml Family Patient of binding
Spectrin 41.0 N. C. A.P. 46.6±4.3
P.A. 44.5+0.7
52.0 Ont. D.W. 55.1±4.0
D.C. 50.7±0.2
Ankyrin 54.5 N. C. A.P. 54.2+4.4
P.A. 52.7±4.5
48.1 Ont. D.W. 48.6+2.4
D.C. 48.8±2.2
* Binding of 125I-spectrin (1 ,ug) to inside-out vesicles (20
,ug protein) was measured (0.2 ml volume, 90 min, 0C), in
the presence and absence of unlabeled spectrin prepared
from patients A.P. and D.W. and unrelated normals P.A. and
D.C. Similarly, binding of '25I-ankyrin (0.4 j.g) to ankyrin-
stripped, inside-out vesicles (10 Ag protein) was measured
(0.2 ml volume, 150 min, 24° C) in the presence and absence
of unlabeled ankyrin. The percent inhibition is derived from
the amount of 125I-spectrin (or 125I-ankyrin) specifically bound
in the presence of unlabeled protein divided by that bound
in the absence. The error is +0.5 the range of duplicates.
Measurements were also made at several other concentra-
tions of unlabeled spectrin and anykyrin, and patient and
control preparations appeared identical (data not shown).
patient A.P. and a control had identical loss of binding
ability when preincubated at several temperatures
above 42.50 as did their ankyrin-stripped, inside-out
vesicles (data not shown). Thus spectrin and ankyrin
from patient cells reassociate in a normal manner with
their respective binding sites and exhibit no change in
thermal sensitivity.
Ankyrin binding sites are abnormal. Experiments
were conducted to compare the ability of ankyrin-
stripped, inside-out vesicles (prepared from different
patients) to bind 125I-ankyrin (prepared from a normal).
The vesicles prepared from patients of both families
bound 24-49% less '25I-ankyrin than vesicles prepared
from unaffected family members or unrelated controls
(Table III). This was reproducible in multiple deter-
minations performed on blood samples obtained from
patients and many controls on several occasions. Both
of the North Carolina patients had reductions in the
'251-ankyrin binding, but both parents had normal
'251-ankyrin binding. The Ontario patient, D.W., had
consistently reduced 1251-ankyrin binding. Of note,
P.W., her son with classical elliptocytosis had nearly
normal 125I-ankyrin binding as did the other siblings
that were analyzed. 125I-Ankyrin binding was normal
in vesicles from two patients with spherocytosis and
three splenectomy patients. It appears that microcy-
tosis, high reticulocyte counts, and absence of the
spleen are not the factors responsible for reduced
ankyrin binding.
Detailed binding experiments were conducted over
wide ranges of 125I-ankyrin concentrations. Plots of
binding data (Fig. 4, left panels) show significantly
reduced 1251-ankyrin binding for all points in the high
affinity region of each profile. Data from these
individuals were analyzed with a computer program
for unconstrained nonlinear regression analysis of
unweighted data in order to resolve curvilinear
Scatchard plots (Fig. 4, middle panels) into linear
components of the best fit (Fig. 4, right panels) with
estimation of the errors (36). This permits evaluation
of differences between patient and control data and
identification of the parameter(s) (B1, KD1, B2, or KD2)
most responsible for the notable reduction in 1251.
ankyrin binding. Each binding profile was resolved
into two lines: one with high affinity (steeper slope --
smaller KD1) but low capacity (smaller intercept on the
abscissa = B1), and one with low affinity (less steep
slope -* larger KD2) but high capacity, (larger intercept
on the abscissa = B2).
Data from these and other experiments are sum-
marized in Table IV. Estimates of B1 for all normal
individuals from the different experiments varied from
21.0 to 31.0 ,ug/mg (mean+SD = 25.9+3.5). Estimates
of B1 for patients A.P., H.P., and D.W. were always
lower than for normals and ranged from 8.4 to 13.7 in
the different experiments (mean±SD = 10.6±2.2).
Note that patient A.P. and patient H.P. had similar
values even though A.P. had undergone a splenectomy
and, at this time, H.P. had not. The statistical
significance of each of these differences in B1 were
determined within experiments 8 and 10: P < 0.10 for
A.P., P < 0.12 for H.P., and P < 0.006 for D.W., when
calculated from a normal distribution (Table IV).
Values ofthe other parameters (KD1, B2 and KD2) were
not consistently different when calculated for patients
and controls. Points in the low affinity region of the
Scatchard plots (points with >40 jig/mg bound)
approach the abscissa asymptotically and are vulner-
able to significant error. When the 125I-ankyrin con-
centrations selected did not result in points of >40
,ug/mg bound, one cannot accurately determine B2 and
KD2 (see experiments 9A and 9B in Table IV). Never-
theless, while experiment 8 indicates that there could
be some reduction in capacity of the low affinity sites
(B2), the estimates contain very wide standard devia-
tions, and therefore reduction of B2 is of little statistical
significance. Indeed, not only is there variation of B2
within an experiment, there are large differences
between experiments (8, 10, Table IV). Because B2 is
invariably much larger than Bl, the total ankyrin bind-
ing capacity (B1 + B2) cannot be considered signifi-
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TABLE III
125I-Ankyrin Binding Determinations*
Exp. Family Patients [1231Ankyrin bound§
% Control
1 N. C. A.P. 51±0
P.A. Unrelated, normal 100+3




P.A. Unrelated, normal 100+5
3 N. C. A.P. 68+1
C.H. Unrelated, splenectomy 94±6
P.A. Unrelated, normal 103±1
M.C. Unrelated, normal 99±0
J.D. Unrelated, normal 100±4
G.T. Unrelated, normal 104±3
4 Ont. D.W. 52±4
M.S. Unrelated, splenectomy 94±6
D.C. Unrelated, normal 100±1
5 Ont. D.W. 71±2
P.W. Son, elliptocytosis 100±1
J.B. Daughter, normal 105±3
B.W. Son, normal 102±3
D.C. Unrelated, normal 100±1
6 Controls H.S. Unrelated, spherocytosis 91±6
S.W. Unrelated, spherocytosis 105±4
P.A. Unrelated, normal 100±6
7 Controls L.R. Unrelated, splenectomy 98±1
J.D. Unrelated, normal 100+1
* These determinations are derived from duplicate values from seven preliminary
experiments. Other similar binding experiments with similar results were obtained
from vesicles prepared from blood samples drawn from members of both families as
well as many unrelated individuals.
t Patients with hemolytic poikilocytosis are listed by initials only (A.P., H.P., and D.W.).
Other family members are identified. Unrelated normals are all adults with no medical
problems. Other unrelated controls are identified and include three persons with
normal erythrocytes who had splenectomies for other reasons. (M.S., C.H., and L.R.)
and two persons with moderately severe hereditary spherocytosis (H.S. and S.W.).
§ Ankyrin binding was performed as described for Fig. 4. In each experiment, all
individual determinations were done with identical membrane protein concentrations
and identical '125I-ankyrin concentrations. These are normalized to the value obtained
from the unrelated normal individual in each experiment (or mean of the values ob-
tained from four normal individuals in experiment 3) ±0.5 ofthe range ofthe duplicates.
cantly different when the different patients and con- When our data were analyzed with this method also, the
trols are compared, and the total capacity may even be reduction in B1 of our patient data greatly outweighed
the same. Determination ofKD1 and KD2 invariably con- changes in KD1 in explaining the differences between
tained wide standard deviations so differences were of patient and control data.
no statistical significance. In summary, ankyrin-stripped, inside-out vesicles
Statistical analysis of curvilinear Scatchard plots is prepared from patients A.P., H.P., and D.W. always had
fraught with difficulty. Another method has also been significant reductions in the ability to bind 125I1
used to assess the contributions of capacity and ankyrin. Computer analysis showed the most statis-
affinity to apparent differences between two plots (39). tically significant explanation to be a 50% reduction in
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FIGURE 4 Effect of increasing the concentration of l25I-ankyrin on binding to ankyrin-stripped
inside-out vesicles. l25I-Ankyrin, in this and all experiments, were prepared from normal individ-
uals. The inside-out vesicles were prepared from patients (A, A.P., and O, D.W.), unrelated normal
individuals (A), and normal family members (A, *). Various concentrations of [1251]ankyrin were
incubated for 150 min at 240C in 0.2 ml vol with 10 ,ug protein of the corresponding ankyrin-
stripped inside-out vesicles. Specifically membrane-bound and free radioactivity were deter-
mined for each point. The data for the points in the high affinity region (<40 ,ug/mg bound) are
plotted in the panels on the left as bound vs. free. The patient values are signi ficantly different from
normals (ranging from P < 0.01 to P < 0.05). The data for all points are plotted according to the
Scatchard equation in the panels in the middle. Each curve appears to be biphasic with, a low
capacity high affinity region and a high capacity low affinity region. Values for these experiments
and others were analyzed by computer to resolve the curvilinear plots into the individual param-
eters. These are plotted in the panels on the right as solid lines for controls and broken lines for
patients and are summarized in Table IV. The number of high affinity sites are indicated on the
abscissa with arrows for patients (BlAp and B1DW) and for normals (BICoN)-
the high affinity binding sites, B1, but without con-
sistent changes in the actual affinity of the interaction
(KD1) or in the affinity (KD2) or capacity (B2) of the low
affinity binding sites. The lack of statistically significant
differences in the total ankyrin binding capacity (B1
+ B2) is consistent with the similarities of the total
content of ankyrin and band 3 of patient membranes
as well as similarities in spectrin binding.
Ankyrin binding sites are normal in solution.
Ankyrin has been shown to bind to the erythrocyte
membrane with high affinity through a specific inter-
action with the cytoplasmic portion ofthe band 3 mole-
cule (29, 32, 40). Controlled enzymatic digestion of
ankyrin-stripped, inside-out vesicles with a-chymo-
trypsin cleaves a water soluble 43,000-dalton fragment
from the cytoplasmic portion of band 3. This poly-
peptide has been purified and has been shown to bind
to ankyrin in solution. Indeed, the soluble peptide will
compete with membrane-associated band 3 for binding
of 125I-ankyrin in solution. When the 43,000-dalton
ankyrin binding fragment of band 3 was prepared from
patient A.P. and a normal control, the preparations
contained identical amounts of protein. Furthermore,
both fragment preparations inhibited the binding of
125I-ankyrin to membranes equivalently. Thus, the
abnormality on the membrane is no longer demon-
strated when the binding sites are in solution.
DISCUSSION
Similar specific defects were found in the membranes
of poikilocytic erythrocytes of three patients from two
different families. The erythrocyte morphology of
each is strikingly abnormal, yet the patients are all in
good health. It was anticipated that the actual
molecular defect would be subtle since an absolute
dysfunction of an essential membrane structure would
probably lead to much more severe hemolysis. Spectrin
and spectrin binding sites (ankyrin) appeared normal.
There was no peculiar heat sensitivity of spectrin,
ankyrin, or membrane vesicles. However, ankyrin-
stripped, inside-out vesicles prepared from these
patients bound significantly less than normal amounts
of 125I-ankyrin. Scatchard analysis indicated that the
most likely explanation is a 50% reduction in the
number of high affinity ankyrin binding sites on the
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TABLE IV
Scatchard Analysis of '251-Ankyrin Binding Experiments*
High affinity sites Low affinity sites
B, KDI B, KD2
Fam-
Exp.t ily Patient n§ Estimate" % P1 Estimate"5 P Estimate' P Estimate" P
8 N. C. A.P. 30 10.8±4.2 (51) <0.1 2.55±+1.60 NS 169±45 NS 179+87 NS
H.P.1t 30 8.8+6.4 (42) <0.12 0.85+1.61 NS 142+21 <0.16 75+31 NS
P.A.§5 30 21.0±4.4 (100) 1.73±0.68 271+82 212±108
9A N. C. A.P. 12 8.4±+19.7 (30) "' 0.01±2.56
J.D.§§ 12 29.7+10.7 (100) 1.49+0.97
9B N. C. A.P. 16 13.7±+12.0 (54) "' 0.57±1.65
G.T.§§ 16 23.3+13.6 (92) "' 1.29+1.29
P.A.§§ 16 25.4±26.8 (100) 1.60+2.48
10 Ont. D.W. 12 11.5+3.1 (46) <0.006 0.01+0.62 <0.13 77+4 NS 51±12 NS
P.W. 12 21.9+7.2 (88) NS 0.94±1.29 NS 169+92 NS 209+204 NS
B.W. 12 25.8+3.4 (104) NS 1.27+0.50 NS 75+7 NS 89+30 NS
J.B. 12 31.0+5.5 (125) NS 2.06+0.84 NS 90+34 NS 162+143 NS
D.C.5§ 12 24.8±3.5 (100) 1.19+0.46 86+6 74+19
* Experiments are described in the legend of Fig. 4. Data were analyzed by Scatchard model test data, nonlinear computer
analysis (36). This allowed calculation of estimates (B,, B2, KD1, KD2) and standard deviations.
t Although different batches of control '25I-ankyrin were used in different experiments, they were prepared identically.
Specific activities were 53,600 cpm/,ug in experiment 8; 72,500 in 9A and 9B; and 87,800 in 10. Binding was measured
over wide ranges of '25I-ankyrin concentrations, but with constant amounts of ankyrin-stripped, inside-out vesicles. Data
from experiments 8 and 10 are plotted in Fig. 4 top and bottom.
§ n, number of individual points measured per binding curve.
11 B, and B2, micrograms of ankyrin bound per milligram of membrane protein +±SD. The percentage (in parentheses) refers to
the patient value when compared with the normal value.
¶ P values of difference calculated from a normal distribution, NS 2 0.20.
** KD, and KD2, micrograms of ankyrin bound per milliliter+SD; multiply by 4.7 to calculate in terms of nanomolarity.
t H.P. underwent a splenectomy subsequent to these determinations.
§§ Unrelated normal individual.
"I In experiment 9A and 9B, all points contained <305 ,g/ml of 2'uI-ankyrin. Most of these points are in the high affinity
area ofthe Scatchard plot (B < 40 /.gimg). Therefore, the SD for B, and KD, are too wide for reasonable calculation ofprobability.
Also, the lack of points in the lower affinity portion of the binding plots make the calculated B2, and KD2 very unreliable.
Nevertheless, estimates of B, agree with the values measured in experiment 8.
membrane. However, when the binding sites were
cleaved from the membrane, identical associations of
ankyrin with the 43,000-dalton fragment preparations
were measured in solution.
We looked specifically for trivial causes of reduced
ankyrin binding capacity but were unable to detect an
artifact that could explain our data. SDS-PAGE failed
to show significant deficiencies or abnormalities of the
individual peptides, and no significant proteolysis was
apparent. There was <5% persistent hemoglobin,
spectrin, or ankyrin on the ankyrin-stripped, inside-out
vesicles, and this could not account for a reduction in
binding capacity (due to persistent occupation of
binding sites or due to an increase in the proportion of
right-side-out vesicles). Also, 125I-spectrin binding was
measured to inside-out vesicles prepared simul-
taneously from the same erythrocytes from which
ankyrin-stripped, inside-out vesicles were prepared,
and these experiments demonstrated that patient and
control vesicles contained identical spectrin binding
capacities (a function of total ankyrin content). Besides
performing the spectrin and ankyrin binding assays on
erythrocytes from these three patients, a relative with
classical elliptocytosis, normal relatives, and unrelated
normals, we investigated erythrocytes from patients
with spherocytosis and other patients who had under-
gone splenectomies. Reduced 125I-ankyrin binding
was found only in erythrocytes from these three
patients, and it does not appear to be an artifact of
cell size, reticulocyte count, or due to absence of
the spleen.
Our conclusion that the number of high affinity
ankyrin binding sites is reduced is based upon
interpretation of curvilinear Scatchard plots. The
patient and control membranes bound 125I-ankyrin
differently (Fig. 4) with individual values distinctly
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FIGURE 5 Inhibition of binding of [125I]ankyrin to ankyrin-
stripped, inside-out vesicles by the 43,000-dalton fragments of
band 3. [125I]Ankyrin and the ankyrin-stripped, inside-out
vesicles were prepared from normal individuals. The 43,000-
dalton fragments of band 3 were prepared from patient (A,
A.P.) and control (0) vesicles by a-chymotrypsin digestion as
described (32), and identical amounts ofprotein were obtained.
[125I]Ankyrin (0.4 ,ug, 72,500 cpm/,ug) was incubated with the
vesicles (9.4 ,tg membrane protein) and various concentra-
tions of the 43,000-dalton fragment in 0.2 ml vol of buffer for
3 h at 0° C. Specifically membrane-bound radioactivity was
determined.
different at all points in the high affinity area (P < 0.05
and frequently P < 0.01). Nevertheless, interpretations
of curvilinear Scatchard plots are vulnerable to error,
and it is often difficult to determine which of the
parameters (B1, KD1, B2, or KD2) is responsible for
apparent differences between plots (39). A change in
any or all parameters would result in a different line,
and it is unlikely that the calculated differences will
be of statistical significance since there is potential
for error at several stages in the experiments. The
abscissa (B = 125I-ankyrin specifically bound) includes
errors in determining the total bound and non-
specifically bound. Determination of unbound 1251_
ankyrin (F) also contains potential error. Therefore,
plotting B/F vs. B results in individual points that
necessarily compound several errors, and since the
binding capacities (B1 and B2) are mutually dependent
and extrapolated values, the confidence limits are
invariably wide. We attempted to reduce potential
errors by performing the measurements at many
different points over a wide range of 125I-ankyrin
concentrations, using vesicles from several different
patients and controls, performing the assays simul-
taneously, and by repeating the binding assays with
fresh preparations of vesicles and 125I-ankyrin on
several occasions. Although computer estimates of B1
were invariably lower for the patients than for controls,
the P values within experiments were sometimes only
suggestive of statistical significance (P < 0.006, P
< 0.10, andP < 0.12). Indeed, when few points existed
in the low affinity region of the curve (experiments 9A
and 9B, Table IV), the confidence limits were so wide
that P values were meaningless even though the
calculated B1 values were close to the values
determined in other experiments (experiments 8 and
10). Nevertheless, the computer calculated values for
B1 were consistently reduced for the patients, whereas
values calculated for KD1, B2, and KD2 were not con-
sistently changed. Therefore, we conclude that a reduc-
tion in the number of high affinity binding sites (B1)
is the most likely explanation.
The detailed molecular explanation for a reduced
number of high affinity ankyrin binding sites is not
understood. Although it is clear that all ankyrin
molecules bind to the cytoplasmic portion of band
3, there is a severalfold excess of potential binding
sites (32, 40, 41). The reasons for this are unclear,
and it is also unclear whether all ankyrin binding
sites are identical. Perhaps more than one popula-
tion of band 3 exists with inherent differences
in the 43,000-dalton region permitting only certain
populations to bind ankyrin, or perhaps all band 3
molecules have identical 43,000-dalton regions with
other factors, such as favorable organization on the
membrane (possibly due to the lipid phase or
glycophorin), responsible for binding of ankyrin.
Certain evidence suggests that the first model is less
likely. The KD of ankyrin binding to membrane and the
K, of ankyrin binding to the 43,000-dalton fragment in
solution are strikingly different (32, 40). The unbound
fraction of band 3 (extracted with Triton X-100) and
total band 3 bind 125I-ankyrin similarly when compared
in solution (29) and when compared in reconstituted
liposomes (40). Also, two-dimensional peptide maps of
ankyrin-bound band 3 and unbound band 3 appear
virtually identical (unpublished data). Some evidence
suggests that band 3 exists on the membrane as a
tetramer (41, 42), and it has been suggested that ankyrin
may bind only to a single member of each band 3
tetramer (40). If the binding sites of our patients' cells
are unfavorably clustered on the membrane, the sites
available for ankyrin binding would appear diminished
due to steric effects while the number of potential sites
would not be reduced when cleaved from the mem-
brane and measured in solution as in Fig. 5. Our data,
like that of Bennett and Stenbuck (32), result in
curvilinear Scatchard plots with apparent high affinity
sites (KD =-5 nM) and "low" affinity sites (KD
= -0.14 ,uM, which is still sufficient to result in a
strong interaction). It is uncertain how these sites are
related. Curvilinear Scatchard plots may not necessarily
indicate a multiplicity of the types of binding sites,
but may result from negative cooperativity affecting a
single class of sites, or curvilinearity may result from
conformational differences within a single population
of receptor types. While the data of Hargreaves et al.
(40) appear to result in linear Scatchard plots,
significant differences in methods of ankyrin prepara-
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tion, vesicle preparation (leaving up to 30% residual
ankyrin), and assay technique may be responsible for
this. The data contained in this report suggest that there
is some difference between the two types of binding
sites since only the high affinity sites are significantly
reduced, and the difference does not appear to be in the
43,000-dalton fragment. Therefore, the apparent
difference between high and low affinity binding sites
may also be due to differences of band 3 conforma-
tion. The interaction between ankyrin and band 3 on
the membrane is complicated and more investigation
is required.
Dacie (43) felt that elliptocytosis represents a
spectrum of disorders due to a series of defects. Our
families may have a related disorder, but the inheritance
patterns are unclear and may be due to various expres-
sions of an abnormal gene even within each family.
Although this report is the first to document a clinical
defect of ankyrin binding sites in abnormally shaped
erythrocytes, other abnormal variants of erythrocyte
cytoskeletons are being discovered (16-21, 44, 45).
Therefore, the defect that we have studied is probably
present in only a small percentage of all cases of
hemolytic anemias. Analysis of membrane protein
interactions in erythrocytes from other hemolytic
families may identify molecular defects responsible for
other disorders. Study of these defects may provide
important insight for further understanding the struc-
ture and function of cell membranes in general.
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